Gyan Chandra

Array ( [id] => 19916213 [patent_doc_number] => 12291566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis [patent_app_type] => utility [patent_app_number] => 17/237650 [patent_app_country] => US [patent_app_date] => 2021-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 51740 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 285 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17237650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17256632 [patent_doc_number] => 20210369617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => LYOPHILIZED MESENCHYMAL STEM CELL DERIVED SECRETOME AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/224068 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518535 [patent_doc_number] => 11708416 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Methods of treating severe insulin resistance by interfering with glucagon receptor signaling [patent_app_type] => utility [patent_app_number] => 17/222236 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 15678 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18947048 [patent_doc_number] => 11890321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-06 [patent_title] => Method of treating or inhibiting glucose intolerance [patent_app_type] => utility [patent_app_number] => 17/203640 [patent_app_country] => US [patent_app_date] => 2021-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5485 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18836810 [patent_doc_number] => 11844867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device [patent_app_type] => utility [patent_app_number] => 17/202119 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 53 [patent_no_of_words] => 24214 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17202119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18962934 [patent_doc_number] => 11896673 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Glucose responsive insulin delivery compositions and methods [patent_app_type] => utility [patent_app_number] => 17/188583 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 57 [patent_no_of_words] => 10215 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356843 [patent_doc_number] => 20220017639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHODS FOR INCREASING THERMOGENIC ADIPOCYTES [patent_app_type] => utility [patent_app_number] => 17/186072 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17186072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18057985 [patent_doc_number] => 20220389071 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-12-08 [patent_title] => LONG-LASTING GLP1 ANALOGUE DRUG FOR TYPE-2 DIABETES [patent_app_type] => utility [patent_app_number] => 17/184248 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18057985 [patent_doc_number] => 20220389071 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-12-08 [patent_title] => LONG-LASTING GLP1 ANALOGUE DRUG FOR TYPE-2 DIABETES [patent_app_type] => utility [patent_app_number] => 17/184248 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18339375 [patent_doc_number] => 20230131324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => FORMULATIONS OF ANTI-ENDOTHELIAL LIPASE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/801670 [patent_app_country] => US [patent_app_date] => 2021-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -90 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18243893 [patent_doc_number] => 20230076204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => SINGLE CHAIN TRIMER MHC CLASS II NUCLEIC ACIDS AND PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/800311 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12610 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569937 [patent_doc_number] => 11318191 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => GLP-1 compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 17/177438 [patent_app_country] => US [patent_app_date] => 2021-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 12510 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17177438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19150159 [patent_doc_number] => 11975049 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-07 [patent_title] => Therapeutic treatment for neurotrophic keratopathy [patent_app_type] => utility [patent_app_number] => 17/176810 [patent_app_country] => US [patent_app_date] => 2021-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 6 [patent_no_of_words] => 3198 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932449 [patent_doc_number] => 20210198338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/174876 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868549 [patent_doc_number] => 20210162016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => METHOD OF DELIVERING A SOMATOSTATIN COMPOUND INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE [patent_app_type] => utility [patent_app_number] => 17/170479 [patent_app_country] => US [patent_app_date] => 2021-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17170479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18271439 [patent_doc_number] => 20230092681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => METHODS FOR THE TREATMENT OF HUNTER SYNDROME [patent_app_type] => utility [patent_app_number] => 17/797644 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -129 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17797644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16853573 [patent_doc_number] => 20210154318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) [patent_app_type] => utility [patent_app_number] => 17/151045 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17151045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483650 [patent_doc_number] => 20230210951 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => IL2 MUTEINS [patent_app_type] => utility [patent_app_number] => 17/785786 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 401 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18334120 [patent_doc_number] => 20230126068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => Insulin Derivative [patent_app_type] => utility [patent_app_number] => 17/758089 [patent_app_country] => US [patent_app_date] => 2020-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17251151 [patent_doc_number] => 11186623 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Ultra-long acting insulin-Fc fusion proteins and methods of use [patent_app_type] => utility [patent_app_number] => 17/135333 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 24374 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17135333 [rel_patent_id] =>[rel_patent_doc_number] =>)